Endothelium Piezo1 deletion alleviates experimental varicose veins by attenuating perivenous inflammation
- PMID: 39249600
- DOI: 10.1007/s11010-024-05115-9
Endothelium Piezo1 deletion alleviates experimental varicose veins by attenuating perivenous inflammation
Abstract
Previous large-scale genetic studies have prioritized the causal genes piezo type mechanosensitive ion channel component 1 (PIEZO1) and castor zinc finger 1 (CASZ1) associated with varicose veins (VVs). This study aims to evaluate their roles in both clinical and experimental VVs. In this study, we investigated abundance of PIEZO1 and CASZ1 in both varicose and normal veins from the same patients. Yoda1 (a selective PIEZO1 agonist, 2.6 mg/kg/day) or vehicle was administered intraperitoneally for 3 weeks to evaluate the effect of PIEZO1 activation on experimental VVs. Subsequently, endothelial Piezo1 deletion mice (Piezo1iΔEC mice) were generated to explored the role of endothelial PIEZO1 on VVs. Laser speckle imaging, flow cytometry, cell tracing with Evans blue or rhodamine-6G, and histopathological staining were utilized to evaluate the pathophysiology of VVs. Our results showed that mRNA expression of PIEZO1, but not CASZ1, was abundant and increased in clinical VVs. The Piezo1tP1-td mice revealed endothelium-specific expression of PIEZO1 in mice veins. By establishing iliac vein ligation-induced VVs in mice, Yoda1 exacerbated experimental VVs with increased inflammatory cell infiltration. Subsequently, endothelial Piezo1 deletion (Piezo1iΔEC mice) alleviated experimental VVs and vascular remodeling by directly reducing vascular permeability and leukocyte-endothelium interactions compared to the control (Piezo1fl/fl mice). PIEZO1 is highly expressed in clinical VVs, meanwhile, activation or inhibition of PIEZO1 exerts a remarkable effect on experimental VVs. Furthermore, Piezo1 may constitute a potential therapeutic approach for the medical treatment of VVs.
Keywords: Endothelial cells; Inflammation; Piezo type mechanosensitive ion channel component 1; Varicose veins; Vascular biology.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interest: The authors declare no competing interests. Ethics approval: This research was approved by the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. The experimental protocol and animal procedures were approved by the Animal Care and Use Committee of the Xiangya Hospital, Central South University, Hunan, China (No.2023030636) and are in accordance with the Guide for the Care and Use of Laboratory Animals.
Similar articles
-
Association of varicose veins with rare protein-truncating variants in PIEZO1 identified by exome sequencing of a large clinical population.J Vasc Surg Venous Lymphat Disord. 2022 Mar;10(2):382-389.e2. doi: 10.1016/j.jvsv.2021.07.007. Epub 2021 Aug 3. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 34358671
-
Piezo1-Mediated Neurogenic Inflammatory Cascade Exacerbates Ventricular Remodeling After Myocardial Infarction.Circulation. 2024 May 7;149(19):1516-1533. doi: 10.1161/CIRCULATIONAHA.123.065390. Epub 2024 Jan 18. Circulation. 2024. PMID: 38235590
-
Ion channel Piezo1 activation aggravates the endothelial dysfunction under a high glucose environment.Cardiovasc Diabetol. 2024 May 3;23(1):150. doi: 10.1186/s12933-024-02238-7. Cardiovasc Diabetol. 2024. PMID: 38702777 Free PMC article.
-
Roles of Piezo1 in chronic inflammatory diseases and prospects for drug treatment (Review).Mol Med Rep. 2025 Jul;32(1):200. doi: 10.3892/mmr.2025.13565. Epub 2025 May 16. Mol Med Rep. 2025. PMID: 40376999 Free PMC article. Review.
-
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Curr Drug Targets. 2013 Mar;14(3):287-324. Curr Drug Targets. 2013. PMID: 23316963 Free PMC article. Review.
Cited by
-
PIEZO1 variant implications for biological understanding and human health.Open Biol. 2025 Jul;15(7):240345. doi: 10.1098/rsob.240345. Epub 2025 Jul 9. Open Biol. 2025. PMID: 40628291 Free PMC article. Review.
References
-
- Atkins E, Mughal NA, Place F, Coughlin PA (2020) Varicose veins in primary care. BMJ (Clinical research ed) 370:m2509. https://doi.org/10.1136/bmj.m2509 - DOI - PubMed
-
- Aslam MR, Asif HM, Ahmad K, Jabbar S, Hayee A, Sagheer MS, Rehman JU et al (2022) Global impact and contributing factors in varicose vein disease development. SAGE Open Med 10:20503121221118990. https://doi.org/10.1177/20503121221118992 - DOI - PubMed - PMC
-
- Hamdan A (2012) Management of varicose veins and venous insufficiency. JAMA 308:2612–2621. https://doi.org/10.1001/jama.2012.111352 - DOI - PubMed
-
- Piazza, Gregory. 2014. Varicose Veins. Circulation 130. American Heart Association: 582–587. https://doi.org/10.1161/CIRCULATIONAHA.113.008331 .
-
- Maeseneer De, Marianne G, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L, Giannoukas A et al (2022) Editor’s Choice—European society for vascular surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg: Off J Eur Soc Vasc Surg 63:184–267. https://doi.org/10.1016/j.ejvs.2021.12.024 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical